Research Consortia

Neuropain

The main objective of the Neuropain project (Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system) are the generation of new neuropathic pain models of high predictive value for the preclinical evaluation of new treatments and the identification of biomarkers of interindividual variation and the effectiveness of treatment in patients.

More information at https://www.upf.edu/web/neuropain

The European Commission's financial support to the project NeuroPain (#HEALTH-F2-2013-602891) is acknowledged.


Phenopain

The Phenopain project (Development of In Vitro Phenotypic Models of Pain and their Application to the High Throughput Screening) aims at the generation of in vitro translational models for their application to drug discovery to predict the therapeutic profile of new drugs in pain.

Phenopain has received funding from the program RETOS-COLABORACIÓN of the Spanish Ministry of Economy, Industry and Competitiveness and has been co-financed by the European Union through the European Regional Development Fund (ERDF).


Flow4Health

The aim of the FLOW4HEALTH project is to create innovative continuous flow processes to synthesize new active pharmaceutical ingredients.

The purpose of FLOW4HEALTH is to facilitate work with hazardous reagents and extreme or delicate reaction conditions so that these can be escalated more predictably and safely by using continuous flow processes. Ultimately, it is about speeding up the first phases of drug research and simultaneously developing innovative laboratory methods and equipment. This will translate into quicker compound purification, improved productivity and efficiency of synthetic processes, and improved sustainability of same.

FLOW4HEALTH has received funding from the program RETOS-COLABORACIÓN of the Spanish Ministry of Economy, Industry and Competitiveness and has been co-financed by the European Union through the European Regional Development Fund (ERDF).


AMMIC

The Catalan Rare Disease Accelerator project (AMMIC, for its acronym in Catalan) is a collaborative network between highly innovative companies and prestigious hospital research centers, including ESTEVE, which aims to promote programs in the field of rare diseases.

ESTEVE's participation in AMMIC focuses on validating and correlating biomarkers of specific monogenic diseases.

The European Union through the European Regional Development Fund (ERDF) has financed the project, awarded by the Agency for Business Competitiveness (ACCIÓ) of the Government of Catalonia.


The HIVACAT and Sanfilippo projects have been supported by the Spanish Ministry of Economy, Industry and Competitiveness through the INNPACTO program and have been co-financed by the European Union through the European Regional Development Fund (ERDF).

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.